Experimental Lung Cancer Therapy Shows Promise
A new dual-action drug demonstrated improved survival rates in clinical trials for patients with advanced lung cancer.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Do you believe the clinical benefits of new cancer drugs justify the high development costs?
Experimental drug tivunatamig showed improved progression-free survival in patients with advanced non-small cell lung cancer compared to tislelizumab in a phase 2 study. The results, presented at the ESMO 2026 Congress, offer a potential new treatment approach for those managing this condition.
Why it matters
This research suggests a new combination therapy may extend survival for patients with advanced lung cancer, a critical need as researchers look for more effective ways to combat tumor growth. The findings highlight a targeted approach that aims to enhance immune system engagement within the tumor environment.
In a phase 2 study of 261 patients with advanced NSCLC, tivunatamig plus chemotherapy demonstrated median progression-free survival of 13.8 months for non-squamous and 13.6 months for squamous cancers, compared to 9.7 and 8.3 months in the tislelizumab control arms.
The players
3SBio
A biotechnology company focused on the development and manufacturing of biopharmaceuticals for cancer and other serious diseases.
Pfizer
A global pharmaceutical company that develops treatments for oncology, immunology, and cardiovascular conditions.
The details
Tivunatamig works by simultaneously targeting the PD-1 immune checkpoint and vascular endothelial growth factor (VEGF). This dual mechanism is designed to block immunosuppressive signals while inhibiting the blood supply tumors need to grow, potentially creating a more favorable environment for the immune system to attack cancer cells. In the trial, patients received a dosage of 10 mg/kg every three weeks.
Timeline
May 2025: Pfizer licensed global rights to tivunatamig outside China.
August 6, 2026: Data cutoff for progression-free survival figures.
October 2026: Phase 2 study data presented at the ESMO 2026 Congress.
Health Landscape
Current cancer treatment relies heavily on PD-1 immune checkpoint inhibitors to help the immune system recognize and fight tumors. This study explores whether adding VEGF inhibition can overcome resistance and provide a more durable response than existing therapies alone.
While these early results are promising, patients with advanced NSCLC should wait for final phase 3 trial data to understand the long-term efficacy of this treatment. It is worth discussing with your oncologist whether you are a candidate for clinical trials as these new combinations emerge.
The takeaway
This phase 2 study indicates that combining immune checkpoint blockade with VEGF inhibition may yield better progression-free survival rates in advanced lung cancer. Patients should track the progress of ongoing clinical trials through their physician as new therapeutic combinations move toward approval.
Further reading
For more on evolving treatment options, visit our Cancer section.
Source note: This article includes information reported by BioPharm International.
Live Poll
Do you believe the clinical benefits of new cancer drugs justify the high development costs?
